In NPC, the Captain study and Polaris-02 study have shown that patients with high PD-L1 expression on tumor cells have better therapeutic efficacy of PD-1 inhibitors compared to patients with low PD-L1 expression [14, 28]. The gene discussed is PDCD1; the disease is neoplasm.